Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomesDr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Persons:
Susan Galbraith
Organizations:
AstraZeneca, Fusion, Fusion Pharmaceuticals